The veterinary vaccines market size is projected to reach US$ 13.67 billion by 2031 from US$ 9.13 billion in 2024. The market is estimated to register a CAGR of 6.0% during 2025-2031. Major factors driving the market growth include increasing pet adoption, heightened awareness of animal health, and rising expenditure on veterinary care. Further, the growing incidence of zoonotic diseases is likely to boost the market during the forecast period. However, high cost associated with vaccine are among the market deterrents.

As per the United Nations (UN) estimation, by 2060, the geriatric population will reach 1.8 billion, which will account for 17.8% of the world's total population. Typical health problems for older adults consist of hearing impairment, cataracts, refractive errors, back and neck discomfort, osteoarthritis, chronic obstructive pulmonary disease, depression, and dementia. Advanced age is also associated with the development of various complex health situations commonly referred to as geriatric syndromes. These often result from a combination of factors and include frailty, urinary incontinence, falls, delirium, and pressure sores. According to Partnership for Quality Home Healthcare, a majority of patients (91%) prefer to get care in their homes, and it is cost-effective.

The increasing ownership of companion animals has heightened awareness regarding pet health and preventive care, ultimately raising the demand for vaccines that protect them from infectious diseases. According to the American Pet Products Association (APPA), the percentage of US households reported owning a pet increased from 67% in 2019 to 70% in 2022. This trend prevails among developed countries and emerging economies such as India and China. These economies have seen a rise in pet adoption due to urbanization and higher disposable income. In September 2022, the World Health Organization (WHO) established vaccination campaigns for zoonoses, such as rabies, that can pass from animals to humans. The WHO promotes elimination campaigns for rabies, which include the vaccination of dogs on a mass scale as a preventive measure. Such initiatives encourage vaccine acceptance in developed and developing regions. In conclusion, the rise in pet ownership and the increasing companion animal population are crucial growth drivers for the veterinary vaccines market. As the pet healthcare industry continues to evolve, the demand for effective vaccines is expected to grow.

Further, the increase in manufacturing plants is a significant growth prospect for the veterinary vaccines market. It solves pressing issues, including production scalability, reducing costs, and making vaccines more accessible regionally. With the soaring demand for veterinary vaccines fueled by increasing pet ownership, livestock husbandry requirements, and international disease prevention programs, producers are spending on new plants and renovating old ones to boost production capacity. In March 2024, Zoetis revealed the acquisition of a 21-acre production facility in Melbourne to increase its existing operations and boost future capacity to produce and develop vaccines for sheep, cattle, dogs, cats, and horses. Boehringer Ingelheim invested more than US$ 209.01 million in 2021 to increase its veterinary vaccine manufacturing plant in Lyon, France, on cutting-edge vaccine technologies such as recombinant vaccines. These expansions add supply to address worldwide demand and reduce the cost of production through economies of scale. Regional manufacturing facilities ensure quicker distribution and lower import reliance, especially in developing countries such as India, Brazil, and Africa. Governments and institutions promote local manufacturing through incentives, such as in India's "Make in India" program, which has promoted local production of veterinary products. These investments provide opportunities for efficiency, innovation, and increased vaccine availability.

The comparative company analysis evaluates and categorizes the veterinary vaccine market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global veterinary vaccine market. The key market players are Boehringer Ingelheim International GmbH, Zoetis Inc, Merck & Co Inc, Virbac SA, Biovac LTD, Neogen Corp, Elanco Animal Health Inc, HIPRA SA, Ceva Sant? Animale, and Ceva Sant? Animale.

Based on technology, the veterinary vaccines market is segmented into live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, and others. The live attenuated vaccines held the largest share of the veterinary vaccines market in 2024, and it is expected to register a significant CAGR during 2024-2031.

By animal type, the market is categorized into companion, livestock, and poultry. The livestock and poultry segment held the largest share of the veterinary vaccines market in 2024. The companion animal segment is further divided into dogs, cats, horses, and others. The livestock and poultry segment is categorized into chicken, cattle, and others.

As per route of administration, the veterinary vaccines market is divided into intramuscular, subcutaneous, and others. The intramuscular segment held a larger share of the veterinary vaccines market in 2024, and it is expected to register a significant CAGR during 2025-2031.

Various organic and inorganic strategies are adopted by companies operating in the veterinary vaccine market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the veterinary vaccine market are listed below.

In February 2025, Zoetis announced that the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, the H5N2 Subtype Killed Virus. The vaccine is labeled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology dat.

In November 2024, Ceva Animal Health (Ceva) - the 5th largest animal health global player, present in 110 countries, unveiled its latest investment in European vaccine manufacturing, with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia.